JPRN-UMIN000029962
Completed
未知
Clinical trial of mesenchymal stem cell mobilization factor KOI2 in epidermolysis bullosa patients - Clinical trial of KOI2 in epidermolysis bullosa patients
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Osaka University Hospital
- Enrollment
- 9
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Epidermolysis bullosa other than malnutrition type (2\) Urine pregnancy test is positive (female only) at screening visit (3\) Breast feeding female patient (4\) HIV, HBs, HCV positive at screening (5\) A subject who participated in other clinical trials within 90 days and received a clinical trial drug (including a placebo) (6\) A subject who is participating in any other clinical trials. (7\) A subject whose liver dysfunction data match the predefined exclusion standard (8\) A subject who has acute worsening of epidermolysis bullosa (such as tracheal/esophageal stenosis, acute nephritis) (9\) Ineligible by other reasons judged by the investigators
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Clinical research using the mesenchymal stem cells from autologous fat tissue of Alzheimer dementiaJPRN-jRCTb050190035OOYAMA TAKAYUKI3
Completed
Not Applicable
Clinical trial of mesenchymal stem cell transplantation for severe heart failureSevere chronic heart failureJPRN-UMIN000000656ational Cardiovascular Center20
Withdrawn
Not Applicable
Application of mesenchymal stem cells in patients with end-stage renal diseaseNL-OMON34665Erasmus MC, Universitair Medisch Centrum Rotterdam16
Recruiting
Phase 1
Cell therapy with use of mesenchymal stem cells in infertile women with Thin EndometriumIRCT20230222057500N1Tehran University of Medical Sciences10
Active, not recruiting
Not Applicable
Mesenchymal stem cell based therapy for the treatment of osteogenesis imperfectaOsteogenesis imperfecta (OI) is a rare genetic disorder with increased bone fragility of varying severity. In the majority of patients the disease is caused by mutations in collagen type I. Severe OI is characterized by osteopenia, frequent fractures, progressive deformity, short stature, loss of mobility, chronic pain and can lead to premature death. At present a cure does not exist.Therapeutic area: Body processes [G] - Cell Physiological Phenomena [G04]EUCTR2012-002553-38-ESItziar Astigarraga Aguirre